Back to Search Start Over

Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis

Authors :
Pierre Duffau
Maya Saleh
Anne Garreau
Emmanuel Ribeiro
Isabelle Douchet
Lionel Couzi
Irène Machelart
Cécile Contin-Bordes
Marc Scherlinger
Patrick Blanco
Jean-Philippe Guegan
Vivien Guillotin
Thierry Schaeverbeke
Patrick Legembre
Marie-Elise Truchetet
Andrea Boizard-Moracchini
Agathe Vermorel
Nathalie Merillon
Jean-François Viallard
Estibaliz Lazaro
Vanja Sisirak
Christophe Richez
Thomas Barnetche
Pierre Vacher
Jean-Luc Pellegrin
Hélène Dumortier
Immunology from Concept and Experiments to Translation (ImmunoConcept)
Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS)
Actions for OnCogenesis understanding and Target Identification in ONcology (ACTION)
Institut Bergonié [Bordeaux]
UNICANCER-UNICANCER-Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM)
CHU Bordeaux [Bordeaux]
Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST)
Université de Limoges (UNILIM)-Université de Limoges (UNILIM)
Immunopathologie et chimie thérapeutique (ICT)
Institut de biologie moléculaire et cellulaire (IBMC)
Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)
SISIRAK, VANJA
Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB)
Bordeaux population health (BPH)
Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2-Institut Bergonié [Bordeaux]
UNICANCER-UNICANCER
Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST)
Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Source :
Science Translational Medicine, Science Translational Medicine, 2021, 13 (600), pp.eabi4994. ⟨10.1126/scitranslmed.abi4994⟩, Science Translational Medicine, American Association for the Advancement of Science, 2021, 13 (600), ⟨10.1126/scitranslmed.abi4994⟩, Science Translational Medicine, American Association for the Advancement of Science, 2021, 13 (600), pp.eabi4994. ⟨10.1126/scitranslmed.abi4994⟩
Publication Year :
2021
Publisher :
HAL CCSD, 2021.

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by a loss of tolerance toward self-nucleic acids, autoantibody production, interferon expression and signaling, and a defect in the regulatory T (Treg) cell compartment. In this work, we identified that platelets from patients with active SLE preferentially interacted with Treg cells via the P-selectin/P-selectin glycoprotein ligand-1 (PSGL-1) axis. Selectin interaction with PSGL-1 blocked the regulatory and suppressive properties of Treg cells and particularly follicular Treg cells by triggering Syk phosphorylation and an increase in intracytosolic calcium. Mechanistically, P-selectin engagement on Treg cells induced a down-regulation of the transforming growth factor–β axis, altering the phenotype of Treg cells and limiting their immunosuppressive responses. In patients with SLE, we found an up-regulation of P- and E-selectin both on microparticles and in their soluble forms that correlated with disease activity. Last, blocking P-selectin in a mouse model of SLE improved cardinal features of the disease, such as anti-dsDNA antibody concentrations and kidney pathology. Overall, our results identify a P-selectin–dependent pathway that is active in patients with SLE and validate it as a potential therapeutic avenue.

Details

Language :
English
ISSN :
19466234 and 19466242
Database :
OpenAIRE
Journal :
Science Translational Medicine, Science Translational Medicine, 2021, 13 (600), pp.eabi4994. ⟨10.1126/scitranslmed.abi4994⟩, Science Translational Medicine, American Association for the Advancement of Science, 2021, 13 (600), ⟨10.1126/scitranslmed.abi4994⟩, Science Translational Medicine, American Association for the Advancement of Science, 2021, 13 (600), pp.eabi4994. ⟨10.1126/scitranslmed.abi4994⟩
Accession number :
edsair.doi.dedup.....c32f1f187cef50609414dae126a2dc43